[EN] USE OF FUCOSYLATION INHIBITOR FOR PRODUCING AFUCOSYLATED ANTIBODY<br/>[FR] UTILISATION D'UN INHIBITEUR DE FUCOSYLATION POUR PRODUIRE UN ANTICORPS AFUCOSYLÉ
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2021127414A1
公开(公告)日:2021-06-24
The present invention provides inhibitors of fucosylation during protein expression from mammalian cells. The inhibitors are derived from rhamnose and act by inhibition of GDP-mannose 4,6-dehydratase (GMD). The invention further provides methods of making proteins with reduced level of fucosylation, such as antibodies and antibodies made by the methods of the present invention. Such hypofucosylated or nonfucosylated antibodies may find use, for example, in treatment of human disease in which is it therapeutically beneficial to direct antibody dependent cellular cytotoxicity (ADCC) mediated killing of cells expressing the antibody target on their surface, for example in depletion of Tregs in cancer patients using a hypofucosylated or nonfucosylated anti-CTLA-4 antibody.
本发明提供了在哺乳动物细胞中蛋白质表达过程中抑制富糖基化的抑制剂。这些抑制剂源自鼠李糖,并通过抑制 GDP-甘露糖4,6-脱水酶(GMD)来发挥作用。该发明还提供了制备具有降低富糖基化水平的蛋白质的方法,例如通过本发明的方法制备的抗体和抗体。这种低富糖化或无富糖化的抗体可以在治疗人类疾病中发挥作用,例如在治疗中对表达抗体靶点的细胞进行抗体依赖性细胞毒作用(ADCC)介导的杀伤,例如在癌症患者中使用低富糖化或无富糖化的抗CTLA-4抗体去除Treg细胞。